Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Aulos Bioscience has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in August 2023.
Aulos Bioscience's investors include Apple Tree Partners.
Aulos Bioscience is headquartered in Cambridge, United States.
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Aulos Bioscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aulos Bioscience — Funding & Investors." VCBacked, August 1, 2023, https://www.vcbacked.co/company/aulos-bioscience. Accessed July 21, 2026.
VCBacked. (2023). Aulos Bioscience — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/aulos-bioscience
{{cite web |title=Aulos Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/aulos-bioscience |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated